- Home
- KNRX vs PCSA Comparison
KNRX vs PCSA Comparison
Compare KNRX & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNRX | PCSA |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 4.2M |
| IPO Year | 2023 | 2012 |
Fundamental Metrics
Financial Performance| Metric | KNRX | PCSA |
|---|---|---|
| Price | $0.08 | $1.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 179.1K | 24.3K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $0.11 |
| 52 Week High | $3.45 | $8.88 |
Technical Indicators
Market Signals| Indicator | KNRX | PCSA |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 50.62 |
| Support Level | N/A | $1.80 |
| Resistance Level | $0.19 | $2.03 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 3.93 | 35.92 |
Price Performance
Historical ComparisonAbout KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.